Inogen Inc Stock Price, News & Analysis

Inogen, a medical technology company, reported Q4 2020 revenue of $74 million, down 6.3% year-over-year, primarily impacted by COVID-19. Domestic B2B sales rose 17.9% to $24.2 million, while rental revenue surged 71.7% to $9.4 million. The company incurred a net loss of $5.1 million and had cash reserves of $231.2 million with no debt. For 2021, Inogen refrained from providing financial guidance due to market uncertainties but anticipates improvements in domestic sales and rental revenue despite expected declines in international and direct-to-consumer sales.

Inogen, Inc. (NASDAQ: INGN) announced the appointment of Kristen Miranda to its Board of Directors, effective March 1, 2021, filling the vacancy left by Scott Beardsley’s resignation. Miranda brings extensive healthcare experience, having served as Aetna’s West Region President since 2017. Her addition aims to enhance payor acceptance of Inogen’s products. CEO Nabil Shabshab emphasized her healthcare background as a key asset for expanding patient access and enhancing shareholder value. The company continues to focus on innovative respiratory solutions for homecare settings.

Inogen, Inc. (NASDAQ: INGN) announced its participation in the 10th Annual SVB Leerink Healthcare Conference, scheduled for February 25, 2021. CEO Nabil Shabshab and CFO Alison Bauerlein will present at 2:20 p.m. ET. The presentation can be accessed via the Investor Relations page on Inogen's website, with a replay available for 90 days post-event. Inogen focuses on developing innovative respiratory products, particularly portable oxygen concentrators for patients with chronic respiratory conditions.

Inogen, Inc. (Nasdaq: INGN) will release its fourth quarter and year-end 2020 financial results on February 24, 2021, after market close. Following the release, a conference call will be held at 1:30 PM PT/4:30 PM ET, where investors can participate by calling (877) 841-3961 domestically or (201) 689-8589 internationally. A replay will be available from February 24, 2021, at 3:30 PM PT until March 10, 2021. Inogen specializes in respiratory products, particularly portable oxygen concentrators for patients with chronic respiratory conditions.

Inogen, Inc. (NASDAQ: INGN) has appointed Nabil Shabshab as President and CEO, effective February 8, 2021, succeeding Scott Wilkinson, who is retiring. Shabshab brings extensive experience from Becton Dickinson, where he served as Worldwide President of Diabetes Care. The Board expressed confidence in Shabshab's leadership to drive growth and enhance patient access to innovative respiratory products. Inogen is recognized for its portable oxygen concentrators aimed at improving the lives of respiratory therapy patients.

Inogen, Inc. (NASDAQ: INGN) has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. The Company’s President and CEO, Scott Wilkinson, along with CFO, Alison Bauerlein, will present on January 12, 2021, at 5:20 p.m. EST. Investors can access a live audio webcast through Inogen's Investor Relations page, with a replay available for 90 days post-event. Inogen specializes in developing and marketing portable oxygen concentrators for patients with chronic respiratory conditions, emphasizing its commitment to innovation in homecare respiratory products.

Inogen (NASDAQ: INGN) announced participation in the Stifel 2020 Virtual Healthcare Conference, where President and CEO Scott Wilkinson, along with CFO Alison Bauerlein, will present on November 17, 2020, at 4:00 p.m. EST. Interested parties can access the live audio webcast via Inogen's Investor Relations page. A replay will be available after the live event for 90 days. Inogen specializes in innovative respiratory products, primarily portable oxygen concentrators for patients with chronic respiratory conditions.

Inogen, Inc. (NASDAQ: INGN) reported Q3 2020 financial results, showing total revenue of $74.3 million, a 19.0% decline year-over-year, primarily attributed to the COVID-19 pandemic. Sequentially, revenue grew by 3.7%. Rental revenue increased by 40.1% to $7.5 million. The company faced a net loss of $1.7 million and an operating loss of $2.0 million. As of September 30, 2020, cash and equivalents stood at $220.5 million with no debt. The company anticipates ongoing adverse impacts from COVID-19 into Q4 2020, with revenue expected to decline compared to Q3.

Inogen, a medical technology company specializing in respiratory products, will announce its third quarter 2020 financial results on November 4, 2020, after market close. The company will host a conference call at 1:30 PM PT/4:30 PM ET for investors and analysts to discuss the results. Interested participants can join by calling the provided numbers or by accessing the live webcast through Inogen's Investor Relations website. A replay of the call will be available until November 18, 2020. For more information, visit the Inogen website.